Actieve functies van Peter Vitins
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Axalbion SA | Directeur/Bestuurslid | - | - |
Axalbion Therapeutics Ltd.
Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Directeur/Bestuurslid | - | - |
Loopbaan van Peter Vitins
Statistieken
Internationaal
Zwitserland | 2 |
Verenigd Koninkrijk | 2 |
Operationeel
Director/Board Member | 2 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Axalbion SA | |
Axalbion Therapeutics Ltd.
Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Health Technology |
- Beurs
- Insiders
- Peter Vitins
- Ervaring